Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 18/20 | 0.62 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.53 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.52 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093897 | 0.80 | SCN9A (0.59) | SCN9ASCN5A | |
| SCHEMBL29835215 | 0.80 | SCN9A (0.59) | SCN9ASCN5A | |
| SCHEMBL1093571 | 0.79 | GLO1 (0.56) | SCN9AGLO1SLC40A1SCN5ASLC22A12 | |
| SCHEMBL1093900 | 0.78 | SCN9A (0.59) | SCN9ASCN5A | |
| SCHEMBL15012142 | 0.78 | SCN9A (0.66) | SCN9ASCN5A | |
| SCHEMBL14699305 | 0.78 | SCN9A (1.00) | SCN9ASCN5A | |
| SCHEMBL1093536 | 0.78 | GLO1 (0.57) | SCN9AGLO1SLC40A1 | |
| SCHEMBL3476637 | 0.77 | SCN9A (0.56) | SCN9AGLO1SLC40A1 | |
| SCHEMBL320536 | 0.77 | SCN9A (0.68) | SCN9ASCN5ASLC22A12 | |
| SCHEMBL15258618 | 0.77 | SCN9A (0.54) | SCN9AGLO1SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630929-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2017-04-25 | — | — | US | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2014-10-02 | — | — | US | disclosed |
| US-20130338111-A1 | Sulfonamide Derivatives | ICAGEN, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | SCN9A 73/4885GLO1 2222/4885SLC40A1 3958/4885 |
| US-20130338111-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | SCN9A 73/4885GLO1 2222/4885SLC40A1 3958/4885 |
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV1, TRPA1, TRPV3 | SCN9A 39/4885GLO1 1951/4885SLC40A1 4027/4885 |
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | SCN9A 73/4885GLO1 2222/4885SLC40A1 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.